Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 2: FD implantation, technical complications, primary safety end point, and other major adverse events at a median 6-month clinical follow-up (range 1–38 months)
FD implantation 
    Attempted treatment (patients/aneurysms) 165/190
    FD implantation at target site (patients/aneurysms) 161 (97.5%)/186 (98%)
    Average No. of devices used per patient 1.2
    Average No. of devices used per aneurysm 1.05
    Average procedure length (min) 79.8
Technical complications 
    Incorrect placement with partial aneurysm coverage 4 (2.1%)
    Guidewire perforation 5 (3.1%)
    Intraoperative thrombus formation (asymptomatic/symptomatic) 6 (3.7%)/0
    Vasospasm 6 (3.7%)
Serious adverse events 
    Any death during the follow-up 7 (4.3%)
    Patients available for follow-up 150 (93.2%)
    Patients lost to or refusing follow-up 11 (6.8%)
    Primary end point (any stroke and neurologic death) 18 (12%)
    Permanent morbidity 9 (6.0%)
    Procedure-related mortality 4 (2.7%)

FD implantation
Attempted treatment (patients/aneurysms)	165/190
FD implantation at target site (patients/aneurysms)	161 (97.5%)/186 (98%)
Average No. of devices used per patient	1.2
Average No. of devices used per aneurysm	1.05
Average procedure length (min)	79.8
Technical complications
Incorrect placement with partial aneurysm coverage	4 (2.1%)
Guidewire perforation	5 (3.1%)
Intraoperative thrombus formation (asymptomatic/symptomatic)	6 (3.7%)/0
Vasospasm	6 (3.7%)
Serious adverse events
Any death during the follow-up	7 (4.3%)
Patients available for follow-up	150 (93.2%)
Patients lost to or refusing follow-up	11 (6.8%)
Primary end point (any stroke and neurologic death)	18 (12%)
Permanent morbidity	9 (6.0%)
Procedure-related mortality	4 (2.7%)